ORMP vs XYL · rev $2.0M vs P/E 27, rev $4.46B
Oramed Pharmaceuticals Inc (ORMP) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Oramed Pharmaceuticals Inc (ORMP) is a biotechnology company listed on US.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
Latest reported ORMP revenue for 2025-09-30 was $2.0M. Net income was $48.4M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. ORMP currently screens at market cap $87.2M.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
ORMP currently screens at market cap $87.2M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the ORMP and XYL stock pages for the full models.
Not investment advice.